BLCO240719C10000
- 4.74
- 0.000.00%
Bausch + Lomb Corp. Newsroom
China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.
Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.
Evercore ISI Group Maintains In-Line on Bausch & Lomb, Raises Price Target to $15.5
Evercore ISI Group analyst Vijay Kumar maintains Bausch & Lomb (NYSE:BLCO) with a In-Line and raises the price target from $15 to $15.5.
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $15.5
Evercore analyst Vijay Kumar maintains $Bausch + Lomb Corp.(BLCO.US)$ with a hold rating, and adjusts the target price from $17 to $15.5.According to TipRanks data, the analyst has a success rate of 4
Bausch + Lomb (NYSE:BLCO) Has A Somewhat Strained Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.Oppe
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Announces Target Price $23
Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 59.9% and
Bausch + Lomb Announces Presentation of New Data at the European Dry Eye Society 2024 Congress
Events Include Symposium on Patient-Centric Approaches to Dry Eye, Highlighting Breakthroughs in Diagnosis, Treatment and Care Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to
Wells Fargo Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $23
Wells Fargo analyst Larry Biegelsen maintains $Bausch + Lomb Corp.(BLCO.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 60.1
Bausch + Lomb INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenses Introduced in the United States
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. introduction of Bausch + Lomb INFUSE for Astigmatism daily
Bausch + Lomb Launches Blink NutriTears Clinically Proven Nutritional Supplement for Dry Eyes in the United States
Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink NutriTears, a clinically proven over-the-counter
Bausch + Lomb Announces 2024 Annual Meeting of Shareholder Results
Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors
Bausch + Lomb Presents New Scientific Data And Evaluations Featuring Consumer, Vision Care And Pharmaceutical Products At Optometry's Meeting June 19-22, 2024
15 ePosters and In-Person Presentations Will Include Clinical Data on Blink NutriTears Supplement for Dry Eyes, Blink Triple Care Lubricating Eye Drops and MIEBO (Perfluorohexyloctane Ophthalmic Solut
Bausch + Lomb's New Intraocular Lens Approved by Health Canada
Bausch + Lomb (BLCO) said Tuesday that Health Canada has approved its enVista Envy full visual range intraocular lens. The company said it plans to introduce additional designs in the coming months to
Bausch + Lomb Receives Health Canada Approval for EnVista Envy * Full Visual Range Intraocular Lens
Bausch + Lomb Shares Rise After Morgan Stanley Upgrade
Bausch + Lomb (BLCO) shares rose 6.7% in recent trading Monday after Morgan Stanley upgraded the company's stock to overweight from equalweight and raised its price target to $18 from $16. Intraday vo
American Airlines To Rally Around 59%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Wedbush rai
Morgan Stanley Upgrades Bausch & Lomb to Overweight, Raises Price Target to $18
Morgan Stanley analyst Patrick Wood upgrades Bausch & Lomb from Equal-Weight to Overweight and raises the price target from $16 to $18.
Damo: Bausch & Lomb (BLCO.US) rating was raised from holding and waiting to increase holdings, and the target price was adjusted from $16.00 to $18.00.
Damo: Bausch & Lomb (BLCO.US) rating was raised from holding and waiting to increase holdings, and the target price was adjusted from $16.00 to $18.00.
Bausch + Lomb Corporation (NYSE:BLCO) Just Reported Earnings, And Analysts Cut Their Target Price
After the latest results, the twelve analysts covering Bausch + Lomb are now predicting revenues of US$4.66b in 2024. If met, this would reflect a meaningful 8.1% improvement in revenue compared to the last 12 months.
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners
Bausch + Lomb Corp. Is Maintained at In-Line by Evercore Partners